Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-21
1996-10-08
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61N 4354
Patent
active
055631436
ABSTRACT:
This invention relates to catechol diether compounds which are inhibitors of tumor necrosis factor (TNF). The catechol diether compounds are useful as inhibitors of TNF per se and in the treatment or alleviation of inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer. This invention also relates to pharmaceutical compositions useful therefor.
REFERENCES:
patent: 4971959 (1990-11-01), Hawkins
Pohlman et al., J. of Immun., 136(12), (1986), p. 4548.
Strieter et al., Science, 243, p. 1467, (1989).
Brennan et al., The Lancet, Jul. 29, 1989, p. 244.
Farahat et al., Ann., Rheum. Dis., 52, (1993), p. 870.
Spooner et al., Clinical Immunology and Immunopathology, 62(1), S11, (1992).
W. Fiers, FEBS, 285(2), p. 199, (1991).
Cohan Victoria L.
Duplantier Allen J.
Benson Gregg C.
Conway John D.
Killos Paul J.
Pfizer Inc.
Richardson P. C.
LandOfFree
Catechol diether compounds as inhibitors of TNF release does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Catechol diether compounds as inhibitors of TNF release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Catechol diether compounds as inhibitors of TNF release will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-57494